Cytovale has received $3.8 million from HHS’ Biomedical Advanced Research and Development Authority (BARDA) for a study of its rapid-sepsis test for COVID-19 patients.

The study is being conducted in Baton Rouge, La., to evaluate the test in patients with potential respiratory infections, including those with SARS-CoV-2.

“The goal of this study is to determine if we can diagnose sepsis quickly and accurately in potential COVID-19 patients and appropriately triage them with the Cytovale technology,” said Hollis O’Neal, leader of the study.